TABLE 2.
Estimated subdistribution hazard ratios (sHR) for acute coronary syndrome (ACS), end-stage renal disease (ESRD), ischaemic stroke, and retinopathy by antiviral treatment status and outcome. sHR analysis included adjustment for inverse probability of treatment weighting and death as a competing risk
| ACS |
ESRD |
Ischaemic stroke |
Retinopathya |
|||||
|---|---|---|---|---|---|---|---|---|
| sHR (95% CI) | P | sHR (95% CI) | P | sHR (95% CI) | P | sHR (95% CI) | P | |
| Full cohort (n = 1242) | ||||||||
| SVR vs untreated | 0.36 (0.25–0.54) | <0.001 | 0.46 (0.31–0.67) | <0.001 | 0.34 (0.21–0.56) | <0.001 | 0.24 (0.17–0.36) | <0.001 |
| TF vs untreated | 0.59 (0.40–0.87) | 0.007 | 1.11 (0.80–1.54) | 0.521 | 0.64 (0.39–1.03) | 0.068 | 0.37 (0.25–0.55) | <0.001 |
| SVR vs TF | 0.62 (0.38–1.02) | 0.057 | 0.41 (0.27–0.63) | <0.001 | 0.53 (0.29–0.98) | 0.044 | 0.66 (0.40–1.10) | 0.110 |
| DAA-treated subcohort vs untreated (n = 988) | ||||||||
| SVR vs untreated | 0.30 (0.19–0.48) | <0.001 | 0.36 (0.22–0.58) | <0.001 | 0.20 (0.10–0.38) | <0.001 | 0.16 (0.08–0.30) | <0.001 |
| TF vs untreated | 1.08 (0.49–2.38) | 0.842 | 0.38 (0.09–1.57) | 0.181 | 0.44 (0.11–1.77) | 0.248 | 0.12 (0.01–1.12) | 0.063 |
| SVR vs TF | 0.28 (0.12–0.66) | 0.004 | 0.94 (0.22–4.10) | 0.935 | 0.45 (0.10–2.02) | 0.297 | 1.29 (0.13–12.76) | 0.826 |
| IFN-treated subcohort vs untreated (n = 733) | ||||||||
| SVR vs untreated | 0.32 (0.17–0.60) | <0.001 | 0.36 (0.19–0.66) | <0.001 | 0.44 (0.21–0.92) | 0.029 | 0.58 (0.34–0.97) | 0.037 |
| TF vs untreated | 0.54 (0.35–0.82) | 0.005 | 0.97 (0.69–1.36) | 0.841 | 0.68 (0.41–1.13) | 0.138 | 0.63 (0.42–0.94) | 0.025 |
| SVR vs TF | 0.60 (0.29–1.23) | 0.162 | 0.37 (0.19–0.71) | 0.003 | 0.65 (0.29–1.49) | 0.313 | 0.92 (0.50–1.67) | 0.777 |
| Cirrhotic (N = 441) | ||||||||
| SVR vs untreated | 0.10 (0.04–0.27) | <0.001 | 0.31 (0.14–0.67) | 0.003 | 0.26 (0.09–0.70) | 0.008 | 0.39 (0.20–0.76) | 0.006 |
| TF vs untreated | 0.18 (0.05–0.59) | 0.005 | 0.72 (0.34–1.53) | 0.392 | 0.54 (0.17–1.69) | 0.286 | 0.38 (0.14–1.01) | 0.052 |
| SVR vs TF | 0.56 (0.12–2.57) | 0.455 | 0.43 (0.17–1.13) | 0.088 | 0.48 (0.12–1.87) | 0.288 | 1.02 (0.36–2.89) | 0.963 |
| Noncirrhotic (N = 801) | ||||||||
| SVR vs untreated | 0.54 (0.35–0.83) | 0.005 | 0.52 (0.34–0.81) | 0.004 | 0.37 (0.21–0.67) | <0.001 | 0.30 (0.18–0.52) | <0.001 |
| TF vs untreated | 0.78 (0.51–1.20) | 0.251 | 1.24 (0.86–1.79) | 0.243 | 0.65 (0.38–1.10) | 0.109 | 0.54 (0.34–0.85) | 0.007 |
| SVR vs TF | 0.70 (0.41–1.17) | 0.172 | 0.42 (0.26–0.68) | <0.001 | 0.58 (0.29–1.15) | 0.120 | 0.56 (0.30–1.06) | 0.075 |
T2D, type II diabetes; ACS, acute coronary syndrome; ESRD, end‐stage renal disease; SVR, sustained virological response; TF, treatment failure; IFN, interferon‐based therapy; sHR, subdistribution hazard ratio.
a
Retinopathy cases within 1 year post index were excluded.